Recurrent, platinum-sensitive ovarian, primary peritoneal or fallopian tube carcinoma.Atezolizumab (anti-PD-L1 mAb) in combination with platinum-based chemotherapy plus concurrent and maintenance bevacizumab. Randomised, triple-blind. This evidence concerns the gene CD274 and fallopian tube carcinoma.